Analytical, biopharmaceutical and regulatory evaluation of topical testosterone preparations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 72, Issue 1, 2009, Pages 275-281

  Baert, B ^a   Annavarapu, S ^a   Burvenich, C ^a   De Spiegeleer, B ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Assay; Comparative quality; Dissolution; Impurities; In vitro drug release; LC UV ESI MS; Regulatory affairs; Specifications; Testosterone; Topical pharmaceuticals

Indexed keywords

TESTOSTERONE;

ARTICLE; DRUG IMPURITY; DRUG QUALITY; DRUG RELEASE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY;

ADMINISTRATION, CUTANEOUS; ANIMALS; CATTLE; CHEMISTRY, PHARMACEUTICAL; DIFFUSION; DRUG DELIVERY SYSTEMS; KINETICS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; SERUM ALBUMIN, BOVINE; SOLUBILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; TECHNOLOGY, PHARMACEUTICAL; TESTOSTERONE;

EID: 62949114291     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.10.014     Document Type: Article

References (25)

1. FDA, SUPAC-SS Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In vitro Release Testing and In vivo Bioequivalence Documentation. in: U.S.D.o.H.a.H. Services (Ed.), Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 1997.
2. Flynn G.L., Shah V.P., Tenjarla S.N., Corbo M., DeMagistris D., Feldman T.G., Franz T.J., Miran D.R., Pearce D.M., Sequeira J.A., Swarbrick J., Wang J.C., Yacobi A., and Zatz J.L. Assessment of value and applications of in vitro testing of topical dermatological drug products. Pharm. Res. 16 9 (1999) 1325-1330
3. Shah V.P., Elkins J.S., and Williams R.L. Evaluation of the test system used for in vitro release of drugs for topical dermatological drug products. Pharm. Dev. Technol. 4 3 (1999) 377-385
4. Hauck W.W., Shah V.P., Shaw S.W., and Ueda C.T. Reliability and reproducibility of vertical diffusion cells for determining release rates from semisolid dosage forms. Pharm Res 24 11 (2007) 2018-2024
5. ICH, Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Products: Chemical Substances, 1999.
6. ICH, Q3A (R2): Impurities in New Drug Substances, 2006.
7. ICH, Q3B (R2): Impurities in New Drug Products, 2006.
8. Monograph 01/2008:2034 Substances for pharmaceutical use, in: European Pharmacopoeia sixth ed., vol. 1, 2007, pp. 703-705.
9. Monograph 01/2008:51000 Control of impurities in substances for pharmaceutical use, in: European Pharmacopoeia 6th Edition, vol. 1, 2007, pp. 653-656.
10. De Spiegeleer B., Vergote V., Pezeshki A., Peremans K., and Burvenich C. Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography-electrospray ionization-mass spectrometry: the obestatin case. Anal. Biochem. 376 2 (2008) 229-234
11. Handelsman D.J. Testosterone: use, misuse and abuse. Med. J. Aust. 185 8 (2006) 436-439
12. Dickinson B., Goldberg L., Elliot D., Spratt D., Rogol A.D., and Fish L.H. Hormone abuse in adolescents and adults - a review of current knowledge. Endocrinologist 15 2 (2005) 115-125
13. Monograph 01/2008:20904 Dissolution test for transdermal pathes, in: European Pharmacopoeia 6th Edition, vol. 1, 2007, pp. 275-277.
14. Emami J., and Tavakoli N. Formulation of sustained-release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation. J. Pharm. Pharmaceut. Sci. 7 3 (2004) 338-344
15. 01/2008:1373 corrected 6.0 Testosterone, in: European Pharmacopoeia 6th Edition, vol. 2, 2007, pp. 3030-3031.
16. Shah V.P. The role of dissolution testing in the regulation of pharmaceuticals: the FDA perspective. In: Dressman J., and Kramer J. (Eds). Pharmaceutical Dissolution Testing (2005), Taylor & Francis Group, New York 81-96
17. Cross S.E., Annisimov Y.G., Magnusson B.M., and Roberts M.S. Bovine-serum-albumin-containing receptor phase better predicts transdermal absorption parameters for lipophilic compounds. J. Invest. Derm. 120 4 (2003) 589-591
18. OECD, Guidance document for the conduct of skin absorption studies, in: OECD Series on Testing and Assessment No. 28, Paris, 2004, p. 21.
19. Veering B.T., Burm A.G., Souverijn J.H., Serree J.M., and Spierdijk J. The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br. J. Clin. Pharmacol. 29 2 (1990) 201-206
20. Macheras P., Reppas C., and Dressman J.B. Biopharmaceutics of Orally Administered Drugs (1995), Ellis Horwood, New York
21. Van Vooren L., Krikilion G., Rosier J., and De Spiegeleer B. A novel bending point criterion for dissolution profile interpretation. Drug Dev. Ind. Pharm. 27 8 (2001) 885-892
22. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use, 2001.
23. Azarmi S., Roa W., and Lobenberg R. Current perspectives in dissolution testing of conventional and novel dosage forms. Int. J. Pharm. 328 1 (2007) 12-21
24. Siewert M., Dressman J., Brown C.K., and Shah V.P. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS Pharm. Sci. Tech. 4 1 (2003) E7
25. Thakker K.D., and Chern W.H. Development and validation of in vitro release tests for semi-solid dosage form-case study. Dissolution Technologies 10 2 (2003) 10-15